Q32 Bio Inc.
About Q32 Bio Inc.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $53.7M
- Net income
- $29.8M
- Total assets
- $61.8M
- Market cap
- $222.3M
- Operating margin
- 31.5%
- Net margin
- 55.5%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $53.7M
- Operating expenses
- $36.8M
- Operating income
- $16.9M
- Income tax
- $0
- Net income
- $29.8M
- EPS (basic)
- $2.42
- EPS (diluted)
- $2.42
Balance sheet
- Total assets
- $61.8M
- Current assets
- $55.0M
- Total liabilities
- $19.8M
- Current liabilities
- $11.3M
- Shareholders’ equity
- $42.0M
Cash flow
- Operating cash flow
- -$33.5M
- Investing cash flow
- $7.0M
- Financing cash flow
- -$3.1M
- Net cash flow
- -$29.7M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $222.3M
- P/E ratio
- 5.0
- EPS (diluted)
- $2.42
- Shares outstanding
- 18.5M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Mar 26, 2024
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $29.8M in FY2025.
- Trading 14% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 5.0.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Q32 Bio Inc..
Write a review
News about Q32 Bio Inc.
News & sentiment via Polygon.io
